Resistance to cancer immunotherapy in metastatic renal cell carcinoma

Abstract

The prognosis of metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically over the years with the emergence of immune checkpoint inhibitors (ICI) used alone, or in combination with another ICI, or with vascular endothelial growth factor receptor tyrosine kinase inhibitor. Although major response rates have been observed with ICI, many patients do not respond, reflecting primary resistance, and durable responses remain exceptional, reflecting secondary resistance. Factors contributing to primary and acquired resistance are manifold, including patient-intrinsic factors, tumor cell-intrinsic factors and factors associated with the tumoral microenvironment (TME). While some mechanisms of resistance are common to several tumor types, others are specific to mccRCC. Predictive biomarkers and alternative strategies are needed to overcome this resistance. This review provides an overview of the major ICI resistance mechanisms, highlights the potential of the TME to induce resistance to ICI, and discusses the predictive biomarkers available to guide therapeutic choice.

Keywords

Tumor microenvironment / clear cell renal cell carcinoma / immune checkpoint inhibitor / immune checkpoint inhibitor resistance

References

[1] Siegel RL,Jemal A.Cancer statistics, 2018..CA Cancer J Clin2018;68:7-30

[2] Rosenblatt J.Immunotherapy for renal cell carcinoma..Hematol Oncol Clin North Am2011;25:793-812

[3] Motzer RJ,Tomczak P,Bukowski RM.Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma..J Clin Oncol2009;27:3584-90 PMCID:PMC3646307

[4] Sternberg CN,Wagstaff J,Mardiak J.A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update..Eur J Cancer2013;49:1287-96

[5] Choueiri TK,Powles T,Mainwaring PN.Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial..Lancet Oncol2016;17:917-27

[6] Motzer RJ,McDermott DF,Hammers HJ.Nivolumab versus everolimus in advanced renal-cell carcinoma..N Engl J Med2015;373:1803-13 PMCID:PMC5719487

[7] Motzer RJ,McDermott DF,Hammers HJ.Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial..Lancet Oncol2019;20:1370-85

[8] Rini BI,Stus V,Hawkins R.Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma..N Engl J Med2019;380:1116-27

[9] Motzer RJ,Haanen J,Albiges L.Avelumab plus Axitinib versus sunitinib for advanced renal-cell carcinoma..N Engl J Med2019;380:1103-15 PMCID:PMC6716603

[10] Khan KA.Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa..Nat Rev Clin Oncol2018;15:310-24

[11] Conforti F,Bagnardi V,Martinetti M.Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis..Lancet Oncol2018;19:737-46

[12] Polanczyk MJ,Vandenbark AA.Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway..J Neurosci Res2006;84:370-8

[13] Polanczyk MJ,Vandenbark AA.Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1)..Int Immunol2007;19:337-43

[14] Chowell D,Pierini F,Rizvi NA.Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy..Nat Med2019;25:1715-20

[15] Chowell D,Grigg CM,Samstein RM.Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy..Science2018;359:582-7 PMCID:PMC6057471

[16] Jouinot A,Goldwasser F.Resting energy metabolism and anticancer treatments..Curr Opin Clin Nutr Metab Care2018;21:145-51

[17] Soldati L,Jirillo E,Marincola FM.The influence of diet on anti-cancer immune responsiveness..J Transl Med2018;16:75 PMCID:PMC5859494

[18] Schmid D.Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis..Ann Oncol Off J Eur Soc Med Oncol2014;25:1293-311

[19] Cortellini A,Palumbo P,Di Marino P.Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study..Sci Rep2020;10:1456 PMCID:PMC6989679

[20] Routy B,Derosa L,Alou MT.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors..Science2018;359:91-7

[21] Elkrief A,Kroemer G,Routy B.The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?.Ann Oncol2019;30:1572-9

[22] Routy B,Daillère R,Wargo JA.The gut microbiota influences anticancer immunosurveillance and general health..Nat Rev Clin Oncol2018;15:382-96

[23] Lalani AK. ASCO GU 2018: antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC). Available from: https://www.urotoday.com/conference-highlights/asco-gu-2018/asco-gu-2018-renal-cancer/102013-asco-gu-2018-antibiotic-use-and-outcomes-with-systemic-therapy-in-metastatic-renal-cell-carcinoma-mrcc.html. [Last accessed on 13 Feb 2020]

[24] Derosa L,Spaziano M,Fidelle M.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer..Ann Oncol2018;29:1437-44 PMCID:PMC6354674

[25] Tinsley N,Villa S,Lorigan P.Cumulative antibiotic use and efficacy of immune checkpoint inhibitors in patients with advanced cancer..J Clin Oncol2018;36:3010

[26] Mahata B,Kolodziejczyk AA,Haim-Vilmovsky L.Single-cell RNA sequencing reveals T helper cells synthesizing steroids de novo to contribute to immune homeostasis..Cell Rep2014;7:1130-42

[27] Arbour KC,Long N,Auclin E.Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer..J Clin Oncol2018;36:2872-8

[28] Santini FC,Wilkins O,Panora E.Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy..J Clin Oncol2017;35:9012

[29] Horvat TZ,Dang TO,Postow MA.Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center..J Clin Oncol2015;33:3193-8 PMCID:PMC5087335

[30] Weber JS,Wolchok JD,Schadendorf D.Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma..J Clin Oncol2017;35:785-92

[31] Wakuda K,Miyawaki E,Kawamura T.The impact of steroid use on efficacy of immunotherapy among patients with lung cancer who have developed immune-related adverse events..J Clin Oncol2019;37:e20583

[32] Fucà G,Poggi M,Proto C.Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors..ESMO Open2019;4:e000457 PMCID:PMC6435242

[33] Chen DS.Oncology meets immunology: the cancer-immunity cycle..Immunity2013;39:1-10

[34] Gubin MM,Schuster H,Ward JP.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens..Nature2014;515:577-81 PMCID:PMC4279952

[35] Yarchoan M,Jaffee EM.Tumor mutational burden and response rate to PD-1 inhibition..N Engl J Med2017;377:2500-1 PMCID:PMC6549688

[36] Labriola M,Gupta R,Jackson J.Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC)..J Clin Oncol2019;37:589

[37] Turajlic S,Xu H,McGranahan N.Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis..Lancet Oncol2017;18:1009-21

[38] Voss MH,Hellmann MD,Hakimi AA.Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC)..J Clin Oncol2018;

[39] Kalbasi A.Tumour-intrinsic resistance to immune checkpoint blockade..Nat Rev Immunol2020;20:25-39

[40] Restifo NP,Kawakami Y,Mulé JJ.Identification of human cancers deficient in antigen processing..J Exp Med1993;177:265-72 PMCID:PMC1950463

[41] Platanias LC.Mechanisms of type-I- and type-II-interferon-mediated signalling..Nat Rev Immunol2005;5:375-86

[42] Zaretsky JM,Shin DS,Hugo W.Mutations associated with acquired resistance to PD-1 blockade in melanoma..N Engl J Med2016;375:819-29 PMCID:PMC5007206

[43] Grivennikov SI,Karin M.Immunity, inflammation, and cancer..Cell2010;140:883-99 PMCID:PMC2866629

[44] Garcia-Diaz A,Moreno BH,Escuin-Ordinas H.Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression..Cell Rep2017;19:1189-201 PMCID:PMC6420824

[45] Bui JD.Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?.Curr Opin Immunol2007;19:203-8

[46] Spranger S,Gajewski TF.Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity..Nature2015;523:231-5

[47] Sweis RF,Bao R,Stadler WM.Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer..Cancer Immunol Res2016;4:563-8 PMCID:PMC4943758

[48] Seiwert TY,Keck MK,Pedamallu CS.Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas..Clin Cancer Res2015;21:632-41 PMCID:PMC4305034

[49] Jiménez-Sánchez A,Pourpe S,Li Y.Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient..Cell2017;170:927-38.e20 PMCID:PMC5589211

[50] Zhao F,Evans KS,DeVito N.Paracrine Wnt5a-β-catenin signaling triggers a metabolic program that drives dendritic cell tolerization..Immunity2018;48:147-60.e7 PMCID:PMC5777287

[51] Zhan T,Boutros M.Wnt signaling in cancer..Oncogene2017;36:1461-73 PMCID:PMC5357762

[52] Boni A,Dang P,Njauw C.Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function..Cancer Res2010;70:5213-9

[53] Ricketts CJ,Fan H,Lang M.The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma..Cell Rep2018;23:313-26.e5 PMCID:PMC6075733

[54] Peng W,Liu C,Creasy C.Loss of PTEN promotes resistance to T cell-mediated immunotherapy..Cancer Discov2016;6:202-16 PMCID:PMC4744499

[55] Goel S,Watt AC,Sceneay J.CDK4/6 inhibition triggers anti-tumour immunity..Nature2017;548:471-5 PMCID:PMC5570667

[56] Jerby-Arnon L,Cuoco MS,Su MJ.A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade..Cell2018;175:984-97.e24 PMCID:PMC6410377

[57] Deng J,Jenkins RW,Dries R.CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation..Cancer Discov2018;8:216-33 PMCID:PMC5809273

[58] Wang X,Chen X.Drug resistance and combating drug resistance in cancer..Cancer Drug Resist2019;2:141-60

[59] Sade-Feldman M,Chen JH,Barzily-Rokni M.Resistance to checkpoint blockade therapy through inactivation of antigen presentation..Nat Commun2017;8:1136

[60] Fridman WH,Sautès-Fridman C.The immune contexture in human tumours: impact on clinical outcome..Nat Rev Cancer2012;12:298-306

[61] Becht E,Lacroix L,Elarouci N.Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression..Genome Biol2016;17:218 PMCID:PMC5073889

[62] Giraldo NA,Pagès F,Verkarre V.Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer..Clin Cancer Res2015;21:3031-40

[63] Vano Y, Rioux-Leclercq N, Dalban C, Sautès-Fridman C, Bougoüin A, Chaput N, et al. 909PDNIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N). Ann Oncol [Internet]. 2019 Oct 1 [cited 2019 Nov 2];30(mdz249.008). Available from: https://doi.org/10.1093/annonc/mdz249.008 [Last accessed on 29 Feb 2020]

[64] Giraldo NA,Vano Y,Lacroix L.Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma..Clin Cancer Res2017;23:4416-28

[65] Zhang S,Long J,Peng J.Immune infiltration in renal cell carcinoma..Cancer Sci2019;110:1564-72 PMCID:PMC6501001

[66] Komohara Y,Ohnishi K,Suzu S.Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma..Cancer Sci2011;102:1424-31

[67] Chanmee T,Konno K.Tumor-associated macrophages as major players in the tumor microenvironment..Cancers2014;6:1670-90 PMCID:PMC4190561

[68] Mier JW.The tumor microenvironment in renal cell cancer..Curr Opin Oncol2019;31:194-9 PMCID:PMC6467495

[69] Santoni M,Amantini C,Maines F.Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma..Cancer Immunol Immunother2013;62:1757-68

[70] Vano YA,Dalban C,Bougoüin A.NIVOREN GETUG-AFU 26 translational study: association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)..J Clin Oncol2020;38:618

[71] Sarvaria A,Saudemont A.B cell regulation in cancer and anti-tumor immunity..Cell Mol Immunol2017;14:662-74 PMCID:PMC5549607

[72] Rosser EC.Regulatory B cells: origin, phenotype, and function..Immunity2015;42:607-12

[73] Helmink BA,Gao J,Basar R.B cells and tertiary lymphoid structures promote immunotherapy response..Nature2020;577:549-55

[74] Petitprez F,Keung EZ,Sun CM.B cells are associated with survival and immunotherapy response in sarcoma..Nature2020;577:556-60

[75] Fridman WH,Sautès-Fridman C.The immune contexture in cancer prognosis and treatment..Nat Rev Clin Oncol2017;14:717-34

[76] Finkin S,Stein I,Weber A.Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma..Nat Immunol2015;16:1235-44 PMCID:PMC4653079

[77] Stubbs M,Griffiths JR.Causes and consequences of tumour acidity and implications for treatment..Mol Med Today2000;6:15-9

[78] Sormendi S.Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironment..Front Immunol2018;9:40 PMCID:PMC5796897

[79] Khan KA.Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa..Nat Rev Clin Oncol2018;15:310-24

[80] Garcia-Lora A,Garrido F.MHC class I antigens, immune surveillance, and tumor immune escape..J Cell Physiol2003;195:346-55

[81] Tatli Dogan H,Bilgin B,Sendur MAN.Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression..Diagn Pathol2018;13:60 PMCID:PMC6109459

[82] Zhang J,Xu X,Mi J.The influence of microenvironment on tumor immunotherapy..FEBS J2019;286:4160-75 PMCID:PMC6899673

[83] Romero-Garcia S,Prado-Garcia H.Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance..Front Immunol2016;7:52 PMCID:PMC4754406

[84] Pan D,Jiang P,Tay RE.A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing..Science2018;359:770-5 PMCID:PMC5953516

[85] Varela I,Raine K,Ong CK.Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma..Nature2011;469:539-42 PMCID:PMC3030920

[86] Miao D,Gao W,Li W.Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma..Science2018;359:801-6 PMCID:PMC6035749

[87] Braun DA,Walsh AM,Wu CJ.Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma..JAMA Oncol2019;5:1631-3 PMCID:PMC6735411

[88] McDermott DF,Atkins MB,Rini BI.Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma..Nat Med2018;24:749-57 PMCID:PMC6721896

[89] Pignon JC,Shukla SA,Horak CE.irRECIST for the evaluation of candidate biomarkers of response to nivolumab in metastatic clear cell renal cell carcinoma: analysis of a phase II prospective clinical trial..Clin Cancer Res2019;25:2174-84 PMCID:PMC6445699

[90] Seeber A,Fritz J,Zimmer KC.High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma..Cancer Sci2018;109:1583-91 PMCID:PMC5980224

[91] Mitchell TC,Smith DC,Wasser JS.Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)..J Clin Oncol2018;36:3223-30 PMCID:PMC6225502

[92] Long GV,Hamid O,Caglevic C.Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study..Lancet Oncol2019;20:1083-97

[93] Cannarile MA,Jacob W,Ries CH.Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy..J Immunother Cancer2017;5:53 PMCID:PMC5514481

[94] Heidegger I,Pichler R.Targeting the tumor microenvironment in renal cell cancer biology and therapy..Front Oncol2019;9: PMCID:PMC6587703

[95] Corrales L,McWhirter SM,Sivick KE.Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity..Cell Rep2015;11:1018-30 PMCID:PMC4440852

[96] Poeck H,Maihoefer C,Tormo D.5’-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma..Nat Med2008;14:1256-63

[97] Granier C,Combe P,Urien S.Tim-3 expression on tumor-infiltrating PD-1+CD8+ T cells correlates with poor clinical outcome in renal cell carcinoma..Cancer Res2017;77:1075-82

[98] He Y,Zhao C,Zhou C.TIM-3, a promising target for cancer immunotherapy..OncoTargets Ther2018;11:7005-9 PMCID:PMC6198883

[99] Long L,Chen F,Phiphatwatchara P.The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy..Genes Cancer2018;9:176-89 PMCID:PMC6305110

[100] Brignone C,Grygar C,Triebel F.A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma..Clin Cancer Res2009;15:6225-31

[101] Shen X.Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis..BMJ2018;362:k3529 PMCID:PMC6129950

[102] Rini BI,Atkins MB,McDermott DF.Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial..Lancet Lond Engl2019;393:2404-15

[103] Choueiri TK,Haanen JBAG,Uemura M.Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)..J Clin Oncol2019;37:101

[104] Beuselinck B,Becht E,Verkarre V.Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting..Clin Cancer Res2015;21:1329-39

[105] Casuscelli J,Fridman WH.Molecular classification of renal cell carcinoma and its implication in future clinical practice..Kidney Cancer2017;1:3-13 PMCID:PMC6179110